FindTrial
Sign In

Safety and efficacy of Daclatasvir and Asunaprevir combination therapy for hemodialyzed patients with genotype 1 chronic hepatitis C infection

Safety and efficacy of Daclatasvir and Asunaprevir combination therapy for hemodialyzed patients with genotype 1 chronic hepatitis C infection - Daclatasvir and Asunaprevir therapy for hemodialyzed ptatients

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000024227
Enrollment
130
Registered
2016-09-29
Start date
2016-09-29
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemodialyzed patients with genotype 1 chronic hepatitis C infection

Interventions

None listed

Sponsors

others
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: hemodialyzed patients with genotype 1 chronic hepatitis C, who initiated on dacalatasvir and asunaprevir between November 2014 and march 2016

Exclusion criteria

Exclusion criteria: 1patients with heart failure 2patients with decompensated cirrhosis 3patients with allergic to NS5A inhibitor or HCV PI inhibitor 4 patients with HCC or other malignant disease

Design outcomes

Primary

MeasureTime frame
Sustained virological response adverse events—

Countries

Japan

Contacts

Public ContactGoki Suda

Hokkaido University Department of Gastroenterology and Hepatology, Graduate School of Medicine,

gsudgast@pop.med.hokudai.ac.jp011-716-1161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026